WHO Africa regional office proposal to address fake medical products

23 August 2016
who-big

Every day, fake medicines and medical products are sold at street corners, in open air markets or on unregulated websites in several countries in the African Region. These poor quality, unsafe medicines and products promote drug resistance and lead to loss of confidence in health professionals, pharmaceutical manufacturers and distributors and in health systems.

In an effort to protect people’s health, the World Health Organization’s regional director for Africa, Matshidiso Moeti, has proposed a strategy aimed at strengthening National Medicine Regulatory Authorities (NMRAs) in order to ensure that only safe, good quality and effective medical products are available in countries. The strategy was presented at the annual meeting of Health Ministers from the WHO African Region (the 66th session of the WHO Regional Committee for Africa) which is taking place in Addis Ababa from 19-23 August 2016.

“Functional regulatory systems ensure that medical products consistently meet international standards and are monitored from clinical evaluation to licensure and use. They play a critical role in protecting people’s health and strengthening health systems to contribute to Universal health Coverage,” said Dr Moeti.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical